Revive Therapeutics Partners With University of Wisconsin-Madison For Psilocybin-Based Research

Revive Therapeutics (CSE: RVV) announced this morning that it has entered into a sponsored research partnership agreement with that of the University of Wisconsin-Madison. The partnership arrangement will see the University of Wisconsin-Madison work with the company to evaluate novel formulations and drug delivery tech focused on psilocybin-based pharmaceuticals.

The program will be conducted at the Reed Research Group, led by Dr Jess D Reed who is the Professor of Animal Sciences at the university. The research agreement with the University and Revive will see the evaluation of psilocybin-based formulations and the patented Tannin-Chitosan composite drug delivery tech for psilocybin. Revive has an exclusive licenses with the Wisconsin Alumni Research Foundation for this technology.

The tech behind the drug delivery method is focused on delivering both synthetic and natural extracts of psilocybin in a number of potential mediums. Potential methods include topical gels, creams or ointments, oral dosages, foams, and oral or transdermal patches. The method is a natural, non-toxic, biodegradable and biocompatible composite. The tech has rapid onset capabilities and may allow for the combining of multiple extracts from mushrooms in a single formulation.

"We are excited to partner with the University of Wisconsin-Madison and leverage our intellectual property of psilocybin-based formulations and our drug delivery technology to advance novel psilocybin-based pharmaceuticals for certain medical needs. We have established a sound foundation to allow us to efficiently develop unique psychedelic-based pharmaceuticals with the objective to investigate our drug products in clinical trials in the U.S."  - Michael Frank, CEO

In addition to the tech having a composite that is derived from a plant group having a number of antibacterial and antifungal properties, it offers licensed pharma firms new product opportunities for various medical disorders.

Revive Therapeutics last traded at $0.14 on the CSE.

FULL DISCLOSURE: Revive Therapeutics is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Revive Therapeutics on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

One thought on “Revive Therapeutics Partners With University of Wisconsin-Madison For Psilocybin-Based Research

  • April 27, 2020 1:05 PM at 1:05 pm

    This doesn’t look any more real or any more fake than the rest of the shroom deals. Not sure how anyone can assess the commercial viability of these.


Leave a Reply